{"id":"NCT01628965","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients","officialTitle":"An Open-label Long-term Extension Trial From Phase II/III of SPM962 (243-07-001) in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-01","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2012-06-27","resultsPosted":"2014-03-19","lastUpdate":"2014-03-19"},"enrollment":143,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"SPM 962","otherNames":["rotigotine"]}],"arms":[{"label":"SPM 962","type":"EXPERIMENTAL"}],"summary":"Safety of SPM 962 in a once-daily repeated long-term treatment in Parkinson's disease patients who are not concomitantly treated with L-dopa will be investigated with a doses.","primaryOutcome":{"measure":"Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters","timeFrame":"Up to 55 weeks after dosing","effectByArm":[{"arm":"SPM 962","deltaMin":140,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":16},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":143},"commonTop":["Application Site Reaction","Nausea","Nasopharyngitis","Vomiting","Constipation"]}}